Search
Massachusetts Paid Clinical Trials
A listing of 3218 clinical trials in Massachusetts actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
2893 - 2904 of 3218
Massachusetts is currently home to 3218 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Study of the Role of Genetic Modifiers in Hemoglobinopathies
Recruiting
This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).
Gender:
ALL
Ages:
2 years and above
Trial Updated:
03/19/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Sickle Cell Disease, Thalassemia, Beta, Thalassemia Alpha, Hemoglobinopathies
Decompression Versus Decompression and Fusion
Recruiting
Adjacent segment disease (ASD) in the lumbar spine is a well-known sequela of lumbar fusion surgery. The annual incidence of adjacent level re-operation is approximately 3% with a ten-year prevalence of 20-30%. Frequently, the surgical treatment involves decompression of the adjacent level coupled with extension of the instrumentation and fusion. Advocates of this paradigm cite the altered kinematics and biomechanics of levels adjacent to a lumbar fusion mass. Furthermore, decompressed levels ad... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Adjacent Segment Disease
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Recruiting
This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer.
The names of the potential treatments involved in this study are:
* Active surveillance
* FOLFIRI treatment
* Nivolumab treatment
* Encorafenib/Binimetinib/Cetuximab treatment
* Trastuzumab + Pertuzumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Metastatic Colon Cancer, Stage III Colon Cancer
Metastatic Tumor Research and Outcomes Network
Recruiting
The registry aims to collect patient information such as patient demographics, co-morbidities, clinical, diagnostic, and therapeutic data, as well as information on adverse events and HRQOL outcomes specific for patients with metastatic spine tumor(s).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Harvard Medical School Department of Neurosurgery, Boston, Massachusetts
Conditions: Metastatic Spine Tumor
Primary Tumor Research and Outcomes Network
Recruiting
This project aims to establish a network of spine oncology centers dedicated to prospective multicenter research of patients diagnosed with a primary tumor of the spine and will include a comprehensive prospective clinical database which will serve as a shared research platform. Demographic, clinical, diagnostic, and therapeutic variables will be used to answer questions about survival and local recurrence, as well as questions about adverse events (AEs), morbidity data, and health-related quali... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/19/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Spinal Column Tumor
NTS-WBRT in Brain Metastases
Recruiting
This research is being done to assess the quality of life and symptom burden in participants who receive (normal tissue sparing whole brain radiation therapy (NTS-WBRT).
This research study involves:
* NTS-WBRT (normal tissue sparing whole brain radiation therapy)
* Memantine standard of care drug
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Brain Metastases
Video Images About Decisions for Ethical Outcomes in the Emergency Department (VIDEO-ED)
Recruiting
A randomized controlled trial of a video decision aid in the Emergency Department Setting to improve advance care planning documentation.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/18/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Emergencies
Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
Recruiting
The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g. ACE/CHIP and mosaicism).
Gender:
ALL
Ages:
All
Trial Updated:
03/18/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Li-Fraumeni Syndrome, TP53 Gene Mutation, Hereditary Cancer Syndrome, Clonal Hematopoiesis, Mosaicism
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
Recruiting
This research trial is studying a combination of neoadjuvant radiotherapy (RT), immunotherapy (pembrolizumab) and chemotherapy for lymph node-positive, triple negative (TN) or hormone receptor positive/HER2-negative breast cancer.
The names of the study interventions involved in this study are:
* Radiation Therapy (RT)
* Immunotherapy: Pembrolizumab (MK-3475)
* Chemotherapies:
* Paclitaxel
* Doxorubicin (also called Adriamycin)
* Cyclophosphamide
* Carboplatin (optional, and in TN onl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
Sacituzumab Govitecan In TNBC
Recruiting
This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC)
The names of the study drugs involved in this study is:
* Sacituzumab govitecan (SG)
* Pembrolizumab (combination therapy with SG)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, HER2-negative Breast Cancer
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
Recruiting
This is a research study to test the tolerability and clinical effectiveness of the study drug, Letermovir (LET), when used as secondary prophylaxis following treatment of Cytomegalovirus (CMV) infection and disease in a solid organ transplant recipient.
This study is an open label trial in which Letermovir will be prescribed to prevent the recurrence of CMV infection and disease in a solid organ transplant recipient following treatment of CMV infection or disease.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/15/2024
Locations: Tufts Medical Center-Division of Geographic Medicine and Infectious Diseases, Boston, Massachusetts
Conditions: Cytomegalovirus Infections, Infection in Solid Organ Transplant Recipients, Neutropenia, Antiviral Toxicity
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Recruiting
This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indications.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Melanoma, Squamous Cell Carcinoma of Head and Neck